Royalty Pharma raises 2026 receipts guidance as Q2 Portfolio Receipts rise 6%
Royalty Pharma reported second-quarter 2026 results on August 5, 2026 and raised its full-year 2026 Portfolio Receipts guidance to $3,400 million to $3,500 million, from $3,325 million to $3,450 million. Portfolio Receipts rose 6% to $773 million and Royalty Receipts rose 14%, but net income attributable to Royalty Pharma plc fell to $18 million from $32 million, which included a $268 million provision for changes in expected cash flows from financial royalty assets.
Key points
- Q2 2026 Portfolio Receipts were $773 million, up 6% from $727 million; Royalty Receipts grew 14% to $768 million.
- Full-year 2026 Portfolio Receipts guidance raised to $3,400 million to $3,500 million from $3,325 million to $3,450 million.
- Net income attributable to Royalty Pharma plc was $18 million, down from $32 million; Adjusted EBITDA rose 16% to $736 million.
- Company repurchased $45 million of Class A shares in Q2 2026 and held $812 million in cash as of June 30, 2026.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.